Inactive Instrument

Highlights Cyteir Therapeutics, Inc.

Equities

CYTT

US23284P1030

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Cyteir Therapeutics, Inc. Estimates Common Stock Liquidation Distributions	03-20	CI
Cyteir Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-06	CI
Cyteir Therapeutics, Inc. Presents Ongoing Results from a Dose Expansion Cohort of CYT-0851 in Combination with Capecitabine in Advanced Platinum-Resistant Ovarian Cancer	23-10-12	CI
Cyteir Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Cyteir Therapeutics, Inc. Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution	23-06-30	CI
Cyteir Therapeutics, Inc. Presents Results from A Phase 1 Study with CYT-0851	23-06-03	CI
Cyteir Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
CYTEIR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-23	AQ
Cyteir Therapeutics Promotes David Gaiero to Chief Financial Officer	23-02-06	BU
Cyteir Therapeutics Announces Prioritization of CYT-0851 Development	23-01-19	CI
CYTEIR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-07	AQ
Earnings Flash (CYT) CYTEIR THERAPEUTICS Posts Q3 Loss $-0.31	22-11-07	MT
Cyteir Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-07	CI
CYTEIR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-08-08	AQ
Cyteir Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-08	CI
Earnings Flash (CYT) CYTEIR THERAPEUTICS Posts Q2 Loss $-0.34	22-08-08	MT
Cyteir Therapeutics, Inc. Announces CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies	22-06-05	CI
CYTEIR THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-05-05	AQ
Cyteir Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-05	CI
Cyteir Therapeutics Reports Lower Loss for Q4	22-03-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cyteir Therapeutics, Inc.

Equities

CYTT

US23284P1030

Highlights

Filters